Branch AD (2011) ebb tide, or the gathering storm?. Seminars in liver disease.
Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, etal (2014) Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV medicine..
Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, etal (2014) Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology.
Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, etak (2014) Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver international : official journal of the International Association for the Study of the Liver 34.
Ge X, Antoine DJ, Lu Y, Arriazu E, Leung TM, etal (2014) High Mobility Group Box-1 (HMGB1) Participates in the Pathogenesis of Alcoholic Liver Disease (ALD). The Journal of biological chemistry 289.